Viridian Therapeutics Financial Statements
NASDAQ: VRDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viridian Therapeutics revenue and earnings
In fiscal 2025, Viridian Therapeutics generated $70.8 million in revenue, up 23359.9% from fiscal 2024. Viridian Therapeutics reported a net loss of $342.6 million, compared with a loss of $269.9 million a year earlier. Operating margin was -512.9%.
Over the last 5 fiscal years, VRDN's revenue has grown at a 132.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Viridian Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.85M | 302.00K | 314.00K | 1.77M | 2.96M | 1.05M | 4.46M | 8.39M | 4.00M | 3.48M |
| Revenue growth (YoY) | +23359.93% | -3.82% | -82.28% | -40.20% | +182.19% | -76.46% | -46.80% | +109.49% | +15.13% | -39.06% |
| Cost of Revenue | — | — | — | — | — | — | — | — | — | 2.55M |
| Gross Profit | — | — | — | — | — | — | — | — | — | 929.00K |
| Operating Expenses | 434.24M | 299.34M | 254.76M | 136.08M | 82.69M | 111.43M | 46.44M | 41.47M | 30.54M | 20.46M |
| Research & Development | 338.93M | 238.25M | 159.76M | 100.89M | 56.89M | 28.30M | 34.79M | 30.42M | 19.62M | 13.69M |
| Selling, General & Admin | 95.31M | 61.08M | 95.00M | — | — | — | — | — | — | 8.44M |
| Operating Income | -363.39M | -299.04M | -254.45M | -134.30M | -79.73M | -110.38M | -41.98M | -33.08M | -26.53M | -16.99M |
| Interest Expense | 4.95M | 2.20M | 1.33M | 500.00K | 3.00K | 508.00K | 835.00K | 873.00K | 383.00K | 95.00K |
| Other Income (Expense) | 20.79M | 29.09M | 16.72M | 4.43M | 315.00K | 173.00K | 941.00K | 1.25M | 403.00K | 39.00K |
| Income Tax | 0 | — | — | — | — | — | — | — | — | — |
| Net Income | -342.60M | -269.95M | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M | -32.70M | -26.51M | -17.27M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | -5.31 | -4.05 | -6.66 | -31.13 | -20.04 | -1.10 | -1.38 | -28.21 |
| EPS (Diluted) | — | — | -5.31 | -4.05 | -6.66 | -31.13 | -20.04 | -1.10 | -1.38 | -28.21 |
| Shares Outstanding (Basic) | — | — | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 29.60M | 19.24M | 614.02K |
| Shares Outstanding (Diluted) | — | — | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 29.60M | 19.24M | 614.02K |
| EBITDA | -362.94M | -298.50M | -253.93M | -134.05M | -79.61M | -110.14M | -41.69M | -32.80M | -26.22M | -16.65M |
| Gross Margin | — | — | — | — | — | — | — | — | — | 26.72% |
| Operating Margin | -512.91% | -99018.21% | -81035.03% | -7579.23% | -2690.79% | -10512.38% | -941.02% | -394.51% | -662.80% | -488.55% |
| Net Margin | -483.57% | -89387.09% | -75711.46% | -7329.23% | -2680.16% | -10544.29% | -938.65% | -389.97% | -662.30% | -496.81% |
This table shows 10 annual periods of Viridian Therapeutics's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow VRDN's reporting calendar. What is a income statement?